Since this realization, Genolution has spent the last decade extensively researching and developing nucleic acid extraction. Moreover, the company also noticed a gap in the market for faster, more accurate, and cost-effective product development solutions. It thus worked toward addressing these unmet industry requirements tirelessly. The results of Genolution’s efforts and longstanding experience in the field are now presented to the world in the form of Nextractor, a robust automated, and easy-to-use DNA and RNA extraction instrument, the company’s flagship offering.
The Nextractor instrument plays a vital role in supporting downstream genomics processes, extracting nucleic acids in its purest state from various sample types such as blood, saliva, or tissue. The chemistry of Genolution’s reagent further improves the yield quality, directly affecting the downstream applications in next-generation sequencing (NGS) and polymerase chain reaction (PCR) testing. Nextractor’s capabilities particularly shined during the COVID-19 pandemic as Genolution’s devices showcased an impressive processing and turnaround time of 20 minutes that quickly overtook the industry standard of one or two hours.
GENOLUTION: Superior DNA/RNA Extraction Capabilities for MDx, Genomics, and Agricultural Development
The company’s Nextractor line of products has multiple variants for differing sample processing needs. Innovating atop this breakthrough technology, the genomics expert developed Nextractor NX-Junior to accommodate smaller labs and their restrictive budgets. Genolution’s NX-Duo, on the other hand, helps organizations extract genetic substances from 96 samples or extract cfDNA from 24 samples, such as urine and plasma; this feature is expected to be extremely vital in processes requiring high-throughput DNA and RNA extraction in facilities such as genetic testing centers. Moreover, the company’s latest R&D involves automated robotic based liquid handling systems, consisting of sample preparation, extraction, and PCR testing capabilities to better manage epidemics or pandemics, all while reducing the need for manual intervention. The company is also developing its own NGS-based clinical microbiology and infectious diseases assays that could be scalable with its own liquid handling systems.
We believe that our fast, robust, and affordable products can provide researchers with the benefits they need to improve their genomic service